Cargando…

Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib

The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Lan, Liu, Li-Xiong, Huang, Qin, Li, Xue-Ying, Hong, Xiao-Ping, Liu, Dong-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080875/
https://www.ncbi.nlm.nih.gov/pubmed/33936080
http://dx.doi.org/10.3389/fimmu.2021.654376
_version_ 1783685529253969920
author Chen, Yu-Lan
Liu, Li-Xiong
Huang, Qin
Li, Xue-Ying
Hong, Xiao-Ping
Liu, Dong-Zhou
author_facet Chen, Yu-Lan
Liu, Li-Xiong
Huang, Qin
Li, Xue-Ying
Hong, Xiao-Ping
Liu, Dong-Zhou
author_sort Chen, Yu-Lan
collection PubMed
description The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastating psychosocial consequences. Although recent studies have shown promising outcomes of the JAK inhibitors in SLE treatment, the efficacy of tofacitinib in diffuse non-scarring alopecia due to SLE has never been reported. Here we present a 29-year-old SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Furthermore, we have made a systematic review regarding the potential effectiveness of tofacitinib in systemic and cutaneous lupus erythematosus. To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia.
format Online
Article
Text
id pubmed-8080875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80808752021-04-29 Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib Chen, Yu-Lan Liu, Li-Xiong Huang, Qin Li, Xue-Ying Hong, Xiao-Ping Liu, Dong-Zhou Front Immunol Immunology The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastating psychosocial consequences. Although recent studies have shown promising outcomes of the JAK inhibitors in SLE treatment, the efficacy of tofacitinib in diffuse non-scarring alopecia due to SLE has never been reported. Here we present a 29-year-old SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Furthermore, we have made a systematic review regarding the potential effectiveness of tofacitinib in systemic and cutaneous lupus erythematosus. To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia. Frontiers Media S.A. 2021-04-14 /pmc/articles/PMC8080875/ /pubmed/33936080 http://dx.doi.org/10.3389/fimmu.2021.654376 Text en Copyright © 2021 Chen, Liu, Huang, Li, Hong and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Yu-Lan
Liu, Li-Xiong
Huang, Qin
Li, Xue-Ying
Hong, Xiao-Ping
Liu, Dong-Zhou
Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title_full Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title_fullStr Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title_full_unstemmed Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title_short Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
title_sort case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080875/
https://www.ncbi.nlm.nih.gov/pubmed/33936080
http://dx.doi.org/10.3389/fimmu.2021.654376
work_keys_str_mv AT chenyulan casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib
AT liulixiong casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib
AT huangqin casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib
AT lixueying casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib
AT hongxiaoping casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib
AT liudongzhou casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib